Levine Steven R
Stroke Program, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.
CNS Spectr. 2005 Jul;10(7):567-78. doi: 10.1017/s109285290001021x.
Blood disorders have been implicated in approximately 5% to 10% of ischemic stroke, with an increased frequency in younger patients. Most disorders are associated with an increased thrombotic tendency and, therefore, an increased risk of ischemic stroke. Less commonly, a bleeding diathesis may predispose a patient to intracranial hemorrhage. While many conditions predisposing to thrombosis have been associated with stroke, there are relatively few prospective, epidemiological studies addressing hypercoagulable states and arterial stroke compared with the number of studies on the genetic thrombophilias, which are predominantly associated with venous thrombosis. When ordering tests of coagulation in stroke patients, one should keep in mind whether the results will influence therapy and/or patient outcome. It is generally not advocated to screen all stroke patients for a "hypercoagulable workup". Typically, patients to be screened for coagulation defects will have a prior history of one or more unexplained thromboembolic events. The yield for diagnosing a hypercoagulable state is typically greatest for young stroke patients or those with a family history of thrombosis and who have no other explanations for their stroke (cryptogenic stroke). The yield in typically low in unselected ischemic stroke patients and older patients. Treatment of a first stroke with a documented hypercoagulable state is typically long-term or indefinite duration warfarin, although there is a paucity of clinical trial data supporting this clinical approach.
血液系统疾病约占缺血性卒中的5%至10%,在年轻患者中更为常见。大多数血液系统疾病与血栓形成倾向增加有关,因此缺血性卒中风险也会增加。较少见的情况是,出血素质可能使患者易发生颅内出血。虽然许多易导致血栓形成的疾病都与卒中有关,但与主要与静脉血栓形成相关的遗传性易栓症研究数量相比,针对高凝状态和动脉性卒中的前瞻性流行病学研究相对较少。在为卒中患者开具凝血检查时,应考虑检查结果是否会影响治疗和/或患者预后。一般不主张对所有卒中患者进行“高凝状态检查”。通常,需要筛查凝血缺陷的患者既往有一次或多次不明原因的血栓栓塞事件。对于年轻卒中患者或有血栓形成家族史且卒中无其他病因(隐源性卒中)的患者,诊断高凝状态的阳性率通常最高。在未选择的缺血性卒中患者和老年患者中,阳性率通常较低。对于首次发生的有记录的高凝状态的卒中患者,通常采用长期或无限期的华法林治疗,尽管支持这种临床方法的临床试验数据较少。